|
Description
Passes on the bright acid (popular name - to break bloodinflammation):
Is one kind of hemostatic for takes orally theprescription to use
the medicine, also is dermatologist with for thebeautiful white
injection prescription, helps the fresh hall to passthrough the long
time study, confirmed passes on Ming Suan to utilizeon the skin, may
improve the black spot spot flesh cell weak inflammation phenomenon,
may prevent the melanin production, the common flesh even if
receives the ultraviolet ray illumination injury, even the sun-scald
or tanned, crosses the period of time, the melanin or has been able
to by the natural metabolism, restored the normal skin color.
Tranexamic Acid is useful in preventing blood loss in:
menorrhagia (heavy periods), nosebleeds, tooth removal in people
with blood disorders, during surgery and to treat hereditary
angioedema (an allergic condition producing swelling and itching
of the skin). Tranexamic Acid is available in tablet and injection
form.
Tranexamic acid (marketed in the UK under the trade name of "Cyclokapron")
is an antifibrinolytic agent which competitively inhibits the
activation of plasminogen to plasmin. The drug has affinity for the
five lysine-binding sites of plasminogen. It thus promotes clot
stability, and is useful as adjunctive therapy in haemophilia and
some other bleeding disorders. The use of tranexamic acid has
superseded the use of amino caproic acid, which not only has a
shorter plasma half-life but is less potent and more toxic. Trials
several decades ago established that regular treatment with
tranexamic acid alone is of no value in prevention of haemarthroses
in haemophilia. It is particularly valuable in controlling bleeding
in the mouth in haemophilia and von Willebrand's disease, such as in
association with dental surgery. It may also be used to control
menorrhagia and epistaxis in von Willebrand's disease. Tranexamic
acid is also of use in factor XI deficiency, and its use to cover
dental, gynaecological or urological surgery in factor XI-deficient
patients may obviate the need for replacement therapy with
concentrate or plasma.It should not be used to control haematuria in
severe haemophilia, as treatment may precipitate clot colic and even
obstruction of the outflow from the urinary pelvis. Similarly, we do
not use the drug in the setting of thoracic or abdominal surgery, as
this may result in the development of insoluble haematomas.
Tranexamic acid may be given alone or together with standard doses
of coagulation factor concentrate. However, it should not be given
to patients with inhibitory antibodies receiving activated
prothrombin factor concentrates (such as FEIBA or Autoplex) as this
may provoke thromboembolism. If treatment with both agents is deemed
to be necessary, it is recommended that at least six hours should
elapse between the last dose of APCC and the administration of
tranexamic acid. By contrast, tranexamic acid may be usefully used
in combination with recombinant factor VIIa to enhance haemostasis.
Tranexamic acid
|
|
|
CHEMICAL STRUCTURE |
|
CHEMICAL STRUCTURE |
 |
|
|
|
Tranexamic Acid
Significantly Reduces Postoperative Blood Loss in Patients
Undergoing Cementless Total Hip Arthroplasty
Intravenous tranexamic acid administered
immediately before cementless total hip arthroplasty (THA)
significantly reduces postoperative blood loss, particularly in the
first 2 hours after surgery, according to a recent Japanese study.
Several strategies have been implemented to reduce surgical bleeding
and perioperative allogenic blood transfusion requirements. For
example, tranexamic acid is a fibrinolytic inhibitor that is
currently used in cardiopulmonary bypass surgery and is being tested
in joint replacement therapy. Tranexamic acid has been shown to
reduce intraoperative and postoperative bleeding in cemented THA;
however, its use has not yet been tested in cementless THA were
greater blood loss often occurs.
Satoshi Yamasaki, MD, and colleagues at the Osaka Kosei-Nenkin
Hospital, Japan, conducted a prospective, randomised study to
evaluate the efficacy of tranexamic acid in patients undergoing
cementless THA.
The study included 40 patients (37 men and 3 women, average age 58)
with osteoarthritis of the hip who underwent cementless THA under
the same protocol. Twenty patients received intravenous whole-body
tranexamic acid (1000 mg, Transamin, Daiichi Pharmaceutical Co.
Ltd., Japan) 5 minutes before surgical incision. Blood loss was
measured perioperatively and up to 24 hours postoperatively.
Overall, total bleeding was significantly less in patients given
tranexamic acid (mean 1350 mL versus 1667 mL in controls, P<.05).
More specifically, postoperative blood loss was significantly less
than controls up to 12 hours after surgery; though perioperative
blood loss was similar between groups.
The most significant change in postoperative blood loss between
groups occurred within the first 2 hours after surgery. During this
time, patients receiving tranexamic acid lost on average 169 mL of
blood while those not receiving tranexamic acid lost 367 mL
(P<.001). No significant differences were observed beyond 2 hours.
Laboratory analysis also revealed that haemoglobin levels were
significantly higher on days 1 and 7 in the tranexamic acid group
and haematocrit was higher on day 1 as compared to controls.
Notably, in this study there were no reported thromboembolic events
up to 1 month postoperatively and no patients required blood
transfusion.
The authors conclude that "tranexamic acid administered just before
the operation reduced the postoperative blood loss within 12 h and
total bleeding in cementless THA." They also note that "further
investigation is necessary to determine the dosage or timing of this
agent to reduce perioperative and postoperative blood loss in
cementless THA."
Analysis of Tranexamic
acid in cosmetics
|
<
HPLC Conditions 1 > |
|
Column |
CAPCELL PAK C18
UG120 S5: 4.6 mm i.D.×250 mm |
|
Mobile phase |
50mmol/L KH2PO40.2vol%
H3PO4 |
|
Flow rate |
1.0
mL/min |
|
Temperature |
45
℃ |
|
Detect |
ULTRAVIOLET RADIATION 210 nm |
|
Inj.
Vol. |
10
オ
L |
|
<
HPLC Conditions 2 > |
|
Column |
CAPCELL PAK SCX UG80: 4.6 mm i.D.×250 mm
|
|
Mobile phase |
0.1mol/L KH2PO4H2O/CH3CN
= 80/20, pH4.0 (H3PO4) |
|
Flow rate |
1.0
mL/min |
|
Temperature |
40
℃ |
|
Detect |
ULTRAVIOLET RADIATION 210 nm |
|
Inj.
Vol. |
10
L |
|
|
Product Name: Tranexamic Acid
CAS #: 1197-18-8
Structural Formula:

|
Test Items |
Standard |
|
Appearance |
Offwhite crystal or crystalline powder |
|
Z-isomer(HPLC) |
Not more than 0.50% |
|
4-Aminomethyl benzoic acid |
A270nm≤0.02(c=0.10g/100ml H2O) |
|
Loss on Drying |
Not more than 0.50% |
|
Heavy Metals |
Not more than 10 PPM |
|
Assay (Dtied basis) |
Not less than 99.0% |
|
New drug helps hemophiliacs - tranexamic acid
Hemophiliacs have a hereditary deficiency of certainblood proteins,
or factors, that help clot the blood. Because of this, they may
bleed for a long time following tooth extraction.
The drug,
tranexamic acid, blocks the enzymes thatdissolve clots, thus helping
the hemophiliac's weak clots to survive. The drug can lessen or
eliminate the need for transfusions of blood-clotting factor.
Effect of
Tranexamic Acid on Blood Loss Reduction After Cardiopulmonary Bypass
Objective:
We evaluated the effect of tranexamic acid on blood loss in patients
undergoing elective cardiopulmonary bypass for coronary artery
bypass surgery.
Methods: We randomly assigned 7 of 14 patients to a group
receiving 50 mg/kg tranexamic acid before skin incision and after
the start of cardiopulmonary bypass and the other 7 as controls.
Results: Intraoperative and postoperative blood loss was
significantly (p = 0.025) reduced in the tranexamic acid group. A
similar decrease in platelet count was observed during
cardiopulmonary bypass in both groups. Antithrombin III was
significantly (p = 0.013) decreased in both groups during
cardiopulmonary bypass. Antithrombin III and thrombin- antithrombin
III complexes were significantly (p = 0.001) increased after
protamine administration. A significant (p = 0.010) decrease in
a2-plasmin inhibitor was noted at 5 and 60 minutes after the start
of cardiopulmonary bypass in the tranexamic acid group. a2-plasmin
inhibitor-plasmin complexes were significantly (p = 0.001) increased
after the start of cardiopulmonary bypass in both groups and were
significantly (p = 0.012) decreased after protamine administration.
a2-plasmin inhibitor-plasmin complexes in the tranexamic acid group
were significantly (p = 0.030) lower than in controls 60 minutes
after the start of cardiopulmonary bypass, just prior to the end of
cardiopulmonary bypass, and after protamine administration.
Conclusions: These findings showed that tranexamic acid
administration effectively prevented perioperative blood loss
without thromboembolic complications and that tranexamic acid during
cardiopulmonary bypass coordinates the anticoagulative effect of
heparin and the antifibrinolytic effect of tranexamic acid.
Effect of Tranexamic Acid
Passes on Ming Suanchien to have guarantees, anti- oxidized, the promotion
blood circulation, the sterilization effect wet, can penetrate the
flesh internal inhibition melanin production and the promotion
metabolism
Simultaneously can
sterilize guarantees of the tax to live the improvement ultraviolet
ray injury to produce roughly, enable the
flesh brightly to have the gloss, but also can prevent the black spot
class to form, achieves the best American white effect.
The black spot size, the melanin precipitation density, and the spot
precipitation area three aspects all obtain the quite good
improvement besides the spot desalination. Gloomily sinks in skin
color transparent feeling and the partial skin block in the
improvement all to have the satisfying effect because the
elimination spot shadow result also causes the whole myo- color
bright feeling upward promotion.
Before Taking Tranexamic Acid
Before
taking Tranexamic Acid make sure your doctor or pharmacist knows:
-
if you are
pregnant, trying for a baby or breast-feeding
-
if you suffer from
kidney problems
-
if you suffer from
any blood clotting problems, such as thrombosis
-
if you are
experiencing, or have ever noticed, blood in your urine
-
if you are taking
any other medicines, including those available to buy
without a prescription, herbal and complementary medicines
How to Take Tranexamic Acid
·
Always read the manufacturer's information leaflet, if possible,
before beginning treatment.
·
Take
Tranexamic Acid exactly as directed by your doctor.
·
Try
to take Tranexamic Acid at the same times each day to avoid missing
doses.
·
If
you are taking Tranexamic Acid for menorrhagia (heavy periods), do
not start taking the medicine until your period has started.
·
This
medicine is for you. Never give it to others, even if their
condition appears to be the same as yours.
·
Never take more than the prescribed dose. If you suspect that you or
someone else has taken an overdose of Tranexamic Acid contact your
doctor or go to the accident and emergency department of your local
hospital at once. Always take the container with you, if
possible, even if it is empty.
Getting the most from your treatment
·
Before taking any 'over-the-counter' medicines, check with your
pharmacist which medicines are safe for you to take alongside
Tranexamic Acid.
·
Keep
your regular appointments with your doctor so your progress can be
checked.
·
If
you are taking Tranexamic Acid for a long time your doctor may want
you to have regular eye examinations and liver function tests.
·
Tranexamic Acid can occasionally cause problems with eyesight. Make
sure you know your eyesight is unaffected before you drive, operate
machinery or do any other jobs which could be dangerous if you were
not able to see properly.
Can Tranexamic Acid cause problems?
As well
as their useful effects all medicines can cause unwanted side
effects. Speak to your doctor or pharmacist if any of the following
side effects continue or become troublesome.
Feeling
or being sick or diarrhoea.
If you
experience problems with your eyesight (particularly with seeing
colours) after taking Tranexamic Acid, contact your doctor as
soon as possible.
If you
experience any other worrying or troublesome symptoms, which you
think may be due to this medicine, discuss them with your
pharmacist.
How to store Tranexamic Acid
-
Keep out of
the reach of children.
-
Store in a
cool, dry place, away from direct light and heat.
-
Do not keep
any out of date medicines. Discard them safely out of the reach
of children or take them to your pharmacist who will dispose of
them for you.
|